Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Sr VP Scientific/Regulatory | March 09, 2021 | March 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date March 09, 2021 · Filed March 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2031-03-08 | Direct | 400,000 |
Reported balance
After 2021-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-09 · Grant · Acquired 400,000 · Balance 400,000 F1: The option is durational-based. No option shares are vested on the date of grant. Twenty-five percent (25%) of the option shares vest and become exercisable on each of the following dates: September 1, 2021, March 1, 2022, September 1, 2022, and March 1, 2023, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is durational-based. No option shares are vested on the date of grant. Twenty-five percent (25%) of the option shares vest and become exercisable on each of the following dates: September 1, 2021, March 1, 2022, September 1, 2022, and March 1, 2023, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2021 Filed Mar 11, 2021 16:51 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001510964-21-000004 · wf-form4_161549946302123.xml · derivative · entry 1 MacKay Douglas Jesse · CIK 0001804634 · Sr VP Scientific/Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-03-08 F1 · derivative.exercise_date: The option is durational-based. No option shares are vested on the date of grant. Twenty-five percent (25%) of the option shares vest and become exercisable on each of the following dates: September 1, 2021, March 1, 2022, September 1, 2022, and March 1, 2023, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.